Advantage of achieving deep response following frontline daratumumab-VTd compared to VRd in transplant-eligible multiple myeloma: multicenter study.

IF 2.3 Q2 HEMATOLOGY Blood Research Pub Date : 2023-06-30 DOI:10.5045/br.2023.2023005
Ja Min Byun, Sung-Soo Park, Sung-Soo Yoon, Ari Ahn, Myungshin Kim, Jung Yeon Lee, Young-Woo Jeon, Seung-Hwan Shin, Seung-Ah Yahng, Youngil Koh, Chang-Ki Min
{"title":"Advantage of achieving deep response following frontline daratumumab-VTd compared to VRd in transplant-eligible multiple myeloma: multicenter study.","authors":"Ja Min Byun,&nbsp;Sung-Soo Park,&nbsp;Sung-Soo Yoon,&nbsp;Ari Ahn,&nbsp;Myungshin Kim,&nbsp;Jung Yeon Lee,&nbsp;Young-Woo Jeon,&nbsp;Seung-Hwan Shin,&nbsp;Seung-Ah Yahng,&nbsp;Youngil Koh,&nbsp;Chang-Ki Min","doi":"10.5045/br.2023.2023005","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The goal of induction therapy for multiple myeloma (MM) is to achieve adequate disease control. Current guidelines favor triplet (bortezomib-lenalidomide-dexamethasone; VRd) or quadruplet regimens (daratumumab, bortezomib-thalidomide-dexamethasone; D-VTd). In the absence of a direct comparison between two treatment regimens, we conducted this study to compare the outcomes and safety of VRd and D-VTd.</p><p><strong>Methods: </strong>Newly diagnosed MM patients aged >18 years who underwent induction therapy followed by autologous stem cell transplantation (ASCT) between November 2020 and December 2021 were identified. Finally, patients with VRd (N=37) and those with D-VTd (N=43) were enrolled.</p><p><strong>Results: </strong>After induction, 10.8% of the VRd group showed stringent complete remission (sCR), 21.6% showed complete response (CR), 35.1% showed very good partial response (VGPR), and 32.4% showed partial response (PR). Of the D-VTd group, 9.3% showed sCR, 34.9% CR, 48.8% VGPR, and 4.2% PR (VGPR or better: 67.6% in VRd vs. 93% in D-VTd, P=0.004). After ASCT, 68.6% of the VRd group showed CR or sCR, while 90.5% of the D-VTd group showed CR or sCR (P=0.016). VRd was associated with an increased incidence of skin rash (P=0.044). Other than rashes, there were no significant differences in terms of adverse events between the two groups.</p><p><strong>Conclusion: </strong>Our study supports the use of a front-line quadruplet induction regimen containing a CD38 monoclonal antibody for transplant-eligible patients with newly diagnosed MM.</p>","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a0/ef/br-58-2-83.PMC10310489.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5045/br.2023.2023005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The goal of induction therapy for multiple myeloma (MM) is to achieve adequate disease control. Current guidelines favor triplet (bortezomib-lenalidomide-dexamethasone; VRd) or quadruplet regimens (daratumumab, bortezomib-thalidomide-dexamethasone; D-VTd). In the absence of a direct comparison between two treatment regimens, we conducted this study to compare the outcomes and safety of VRd and D-VTd.

Methods: Newly diagnosed MM patients aged >18 years who underwent induction therapy followed by autologous stem cell transplantation (ASCT) between November 2020 and December 2021 were identified. Finally, patients with VRd (N=37) and those with D-VTd (N=43) were enrolled.

Results: After induction, 10.8% of the VRd group showed stringent complete remission (sCR), 21.6% showed complete response (CR), 35.1% showed very good partial response (VGPR), and 32.4% showed partial response (PR). Of the D-VTd group, 9.3% showed sCR, 34.9% CR, 48.8% VGPR, and 4.2% PR (VGPR or better: 67.6% in VRd vs. 93% in D-VTd, P=0.004). After ASCT, 68.6% of the VRd group showed CR or sCR, while 90.5% of the D-VTd group showed CR or sCR (P=0.016). VRd was associated with an increased incidence of skin rash (P=0.044). Other than rashes, there were no significant differences in terms of adverse events between the two groups.

Conclusion: Our study supports the use of a front-line quadruplet induction regimen containing a CD38 monoclonal antibody for transplant-eligible patients with newly diagnosed MM.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在符合移植条件的多发性骨髓瘤中,与VRd相比,一线daratumumab-VTd获得深度缓解的优势:多中心研究
背景:诱导治疗多发性骨髓瘤(MM)的目的是达到充分的疾病控制。目前的指南倾向于三联用药(硼替佐米-来那度胺-地塞米松;VRd)或四联体方案(达拉单抗、硼替佐米-沙利度胺-地塞米松;D-VTd)。在缺乏两种治疗方案之间的直接比较的情况下,我们进行了这项研究来比较VRd和D-VTd的结果和安全性。方法:选取在2020年11月至2021年12月期间接受诱导治疗并进行自体干细胞移植(ASCT)的新诊断MM患者,年龄>18岁。最后,入选VRd患者(N=37)和D-VTd患者(N=43)。结果:诱导后,10.8%的VRd组出现严格完全缓解(sCR), 21.6%的VRd组出现完全缓解(CR), 35.1%的VRd组出现非常好的部分缓解(VGPR), 32.4%的VRd组出现部分缓解(PR)。在D-VTd组中,9.3%的患者出现sCR, 34.9%的患者出现CR, 48.8%的患者出现VGPR, 4.2%的患者出现PR (VGPR或更好:VRd组67.6%,D-VTd组93%,P=0.004)。ASCT后,VRd组出现CR或sCR的比例为68.6%,D-VTd组出现CR或sCR的比例为90.5% (P=0.016)。VRd与皮疹发生率增加相关(P=0.044)。除了皮疹外,两组之间的不良事件没有显著差异。结论:我们的研究支持使用含有CD38单克隆抗体的一线四联体诱导方案用于符合移植条件的新诊断MM患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Blood Research
Blood Research HEMATOLOGY-
CiteScore
3.70
自引率
0.00%
发文量
64
期刊最新文献
Recent advances in and applications of ex vivo drug sensitivity analysis for blood cancers. PD-1 inhibitors plus chemotherapy for refractory EBV-positive DLBCL: a retrospective analysis. Back to basics: the coagulation pathway. Real-world experience of emicizumab prophylaxis in Korean children with severe hemophilia A without inhibitors. Absence of canonical mutations in pediatric essential thrombocytosis: a case series.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1